FCDO Minister meets with Jenner Institute researchers
25 January 2024
Mr. Mitchell, along with Professor Charlotte Watts, FCDO Chief Scientific Adviser and Director for Research and Evidence, toured the research facilities of the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute, following the government announcement in Davos of an additional £10 million to support the effective roll-out of two new malaria vaccines both developed by British science.
Scientists receive the European Hector Research Award for HIV
3 November 2023
The AELIX-002 study group research was awarded the European Hector Research Award in HIV for research on the therapeutic vaccine against HIV. The researchers include Prof Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute at NDM.
Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out
2 October 2023
The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant is critical to reducing over half a million malaria-related deaths annually.
Oxford R21/Matrix-M™ malaria vaccine receives regulatory clearance for use in Burkina Faso
24 July 2023
The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Burkina Faso by the country’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).
African Phase I HIV vaccine trial shows encouraging preliminary results
12 July 2023
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully. Preliminary analysis of the immunological trial results demonstrates the induction of high frequencies of broadly specific T cells that recognise functionally conserved regions on HIV-1 and are therefore more protective.
Jenner Institute DPhil Symposium
6 July 2023
The Jenner Institute DPhil Symposium on 23 June 2023 brought together over 80 DPhil Students, Research Assistants, Technicians and Apprentices across the Nuffield Department of Medicine to network and share their research and career aspirations. The day was organised entirely by DPhil Students: Adam Khan-Qureshi, Marco Polo Peralta Alvarez, Rebecca Makinson, Samuel Provstgaard-Morys, Meera Madhavan, Christopher De Voss, and Adam Norton-Steele, with the support from Professor Katie Ewer, Assistant Director of Studies at the Jenner Institute.
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
13 April 2023
The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.
Mexican Ambassador visits Jenner Institute
24 March 2023
The Mexican Ambassador to the United Kingdom, Her Excellency Ms Josefa González-Blanco Ortiz Mena, was given a tour and met with representatives of the Jenner Institute.
Romain Guyon awarded 2022 Michelson Prize
2 February 2023
DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.
Oxford gets £122m funding for healthcare research
14 October 2022
Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.
Blueprint for new adenovirus-based vaccines within 100 days
21 December 2021
Jenner researchers have published a pre-print on how new adenovirus-based vaccines could be produced at large-scale within 100 days of identification of a new virus or variant. They also report an improved manufacturing method which could enable production of 1 billion doses per month. The paper is being submitted to BioRxiv and a peer-reviewed journal, and is temporarily available here:
£50m funding for Poonawalla Vaccines Research Building at Oxford University
15 December 2021
The Poonawalla Vaccines Research Building is to be established at Oxford University's Old Road Campus following a £50m funding commitment from Serum Life Sciences, a subsidiary of Serum Institute of India. The building will be a new home for the Jenner Institute. The donation will be the University’s largest ever gift for vaccines research.
One week left to apply for Vaccinology Training
10 December 2021
In this open call TRANSVAC2 offers free advanced courses on Adjuvants and Vaccine Formulations, Statistics of vaccine evaluation, and Regulatory aspects of vaccine development. Apply until December 15th at www.transvac.org.
Professor Dame Sarah Gilbert delivers BBC Dimbleby Lecture
7 December 2021
Featuring notable speakers from business, science or politics since 1972, Prof. Gilbert delivered the 44th Richard Dimbleby Lecture, held this year at Oxford's Blavatnik School of Government. Dame Sarah Gilbert is the Saïd Professor of Vaccinology, at the Jenner Institute & Nuffield Department of Clinical Medicine. The lecture is available (in the UK) via the BBC iPlayer.
Phase I HIV vaccine trial completes volunteer recruitment in time for World AIDS Day
1 December 2021
The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) is pleased to announce the completion of recruitment of volunteers for the Phase I HIV-CORE 006 HIV vaccine clinical trial at four sites in Kenya, Uganda and Zambia. Enrolment of the final participants took place today at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, on World AIDS Day.
Fighting diseases with cross-species vaccination
30 November 2021
The 2021 Royal Society Africa Prize Seminar will be given by Professor George Warimwe, Jenner Investigator. More than 70% of these infectious diseases are zoonotic, with some causing illness and death in humans as well as the animal host. Professor Warimwe will discuss his ‘one health' approach to developing a single Rift Valley Fever vaccine suitable for humans and livestock. The lecture will take place online 2 December at 6.30pm GMT.
Jenner Institute named Covid Innovation Heroes
29 November 2021
The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award 2021.
Oxford vaccine reaches two billion dose milestone
16 November 2021
University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines.